Gesynta Pharma is a privately held Swedish company located in Stockholm.
Based on research from the Karolinska Institute, Gesynta Pharma develops novel mPGES-1 inhibitors with anti-inflammatory and pain-relieving properties. The drug candidate GS-248 is planned to enter a Phase II clinical trial in patients with endometriosis in 2023. Endometriosis is a painful, chronic, inflammatory, and estrogen-dependent disease that causes great suffering to millions of women.
YEAR OF INVESTMENT
2020
SECTOR
Drug development
LOCATION
Stockholm, Sweden
WEBSITE
htthttps://www.gesynta.se/